HER2-Low Breast Carcinoma

subtype

Identifier: CI-CAN-00005489
Entity page: /cancer/her2-low-breast-carcinoma ↗
Edges: 35

Neighbours: 11 drugs10 trials
Drawn: 21 of 21 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
HER2-Low Breast Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived11 of 11
→ investigated in trials for	Aromatase Inhibitor 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	HER2-Low Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 1 trials (1 active) · roll-up of the cancer and its descendants	—

HER2-Low Breast Carcinoma studied in …STUDIED_INderived10 of 24show all (up to 200)
→ studied in	NCT07796880Phase 2 · recruiting Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive， Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer · condition mapped ONTOLOGY_EXACT · 24 trials mapped (19 active)	—	—	HER2-Low Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06298084Phase 1/Phase 2 · recruiting Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd · condition mapped ONTOLOGY_EXACT · 24 trials mapped (19 active)	—	—	HER2-Low Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05868226Phase 1/Phase 2 · recruiting PRE-ISPY Phase I/II Oncology Platform Program · condition mapped ALIAS · 24 trials mapped (19 active)	—	—	HER2-Low Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06533826Phase 2 · recruiting TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd · condition mapped ALIAS · 24 trials mapped (19 active)	—	—	HER2-Low Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07383506Phase 1 · recruiting A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors · condition mapped ALIAS · 24 trials mapped (19 active)	—	—	HER2-Low Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06144944Phase 3 · active not recruiting Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer · condition mapped ONTOLOGY_EXACT · 24 trials mapped (19 active)	—	—	HER2-Low Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07137416Phase 1 · recruiting Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer · condition mapped CURATED_BROADER · 24 trials mapped (19 active)	—	—	HER2-Low Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05514717Phase 1 · terminated A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 · condition mapped ALIAS · 24 trials mapped (19 active)	—	—	HER2-Low Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06224673Phase 2 · recruiting ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer · condition mapped ONTOLOGY_EXACT · 24 trials mapped (19 active)	—	—	HER2-Low Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07198724Phase 1/Phase 2 · recruiting ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer · condition mapped ONTOLOGY_EXACT · 24 trials mapped (19 active)	—	—	HER2-Low Breast Carcinoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains